NANOG and cancer: Therefore, our results provide a strong rationale for the use of HDAC1 inhibitors as a promising strategy that we believe will be essential to extending the benefit of ICB therapy to larger patient populations, including those with NANOG+ immune-refractory tumors, particularly in immune-based cancer therapy.